AR091908A1 - COMPLEJO CRISTALINO DE 1-CIANO-2-(4-CICLOPROPIL-BENCIL)-4-(b-D-GLUCOPIRANOS-1-IL)-BENCENO, METODOS PARA SU PREPARACION Y SU USO PARA PREPARAR MEDICAMENTOS - Google Patents
COMPLEJO CRISTALINO DE 1-CIANO-2-(4-CICLOPROPIL-BENCIL)-4-(b-D-GLUCOPIRANOS-1-IL)-BENCENO, METODOS PARA SU PREPARACION Y SU USO PARA PREPARAR MEDICAMENTOSInfo
- Publication number
- AR091908A1 AR091908A1 ARP130102660A ARP130102660A AR091908A1 AR 091908 A1 AR091908 A1 AR 091908A1 AR P130102660 A ARP130102660 A AR P130102660A AR P130102660 A ARP130102660 A AR P130102660A AR 091908 A1 AR091908 A1 AR 091908A1
- Authority
- AR
- Argentina
- Prior art keywords
- benzene
- preparation
- methods
- glucopiranos
- ciclopropil
- Prior art date
Links
- UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Substances C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 title abstract 2
- 229940079593 drug Drugs 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title abstract 2
- -1 4-cyclopropyl-benzyl Chemical group 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/10—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
- C07H7/04—Carbocyclic radicals
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Pyrane Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12177944 | 2012-07-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR091908A1 true AR091908A1 (es) | 2015-03-11 |
Family
ID=48874313
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP130102660A AR091908A1 (es) | 2012-07-26 | 2013-07-25 | COMPLEJO CRISTALINO DE 1-CIANO-2-(4-CICLOPROPIL-BENCIL)-4-(b-D-GLUCOPIRANOS-1-IL)-BENCENO, METODOS PARA SU PREPARACION Y SU USO PARA PREPARAR MEDICAMENTOS |
Country Status (23)
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9145434B2 (en) | 2012-07-26 | 2015-09-29 | Boehringer Ingelheim International Gmbh | Crystalline complex of 1-cyano-2-(4-cyclopropyl-benzyl)-4-(ss-d-glucopyranos-1-yl)-benzene, methods for its preparation and the use thereof for preparing medicaments |
| PL2981269T3 (pl) | 2013-04-04 | 2024-02-05 | Boehringer Ingelheim Vetmedica Gmbh | Leczenie zaburzeń metabolicznych u zwierząt koniowatych |
| ES2859905T3 (es) | 2013-12-17 | 2021-10-04 | Boehringer Ingelheim Vetmedica Gmbh | Inhibidores de SGLT2 para el tratamiento de trastornos metabólicos en animales felinos |
| US10603300B2 (en) * | 2014-01-23 | 2020-03-31 | Boehringer Ingelheim Vetmedica Gmbh | Treatment of metabolic disorders in canine animals |
| ES2811261T3 (es) * | 2014-04-01 | 2021-03-11 | Boehringer Ingelheim Vetmedica Gmbh | Tratamiento de trastornos metabólicos en animales equinos |
| CN103965020B (zh) * | 2014-05-06 | 2015-09-09 | 启东东岳药业有限公司 | 制备5-碘-2-溴苄醇的方法 |
| ES2991763T3 (es) | 2014-09-25 | 2024-12-04 | Boehringer Ingelheim Vetmedica Gmbh | Tratamiento de combinación de inhibidores de SGLT2 y agonistas de dopamina para la prevención de trastornos metabólicos en animales equinos |
| PT3202772T (pt) * | 2014-09-30 | 2020-11-20 | Jiangsu Hengrui Medicine Co | Cristal de um complexo de l-prolina/inibidor do cotransportador de sódio-glicose 2 |
| CZ2015110A3 (cs) * | 2015-02-18 | 2016-08-31 | Zentiva, K.S. | Pevné formy empagliflozinu |
| CN107995862B8 (zh) | 2015-08-27 | 2021-12-03 | 勃林格殷格翰维特梅迪卡有限公司 | 包含sglt-2抑制剂之液态药物组合物 |
| WO2017203457A1 (en) * | 2016-05-26 | 2017-11-30 | Dr. Reddy's Laboratories Limited | Solid state forms of empagliflozin |
| KR102226465B1 (ko) * | 2016-05-28 | 2021-03-11 | 하이난 수안주 파마 코포레이션 리미티드 | 나트륨-글루코스 공수송체 2에 대한 억제제의 결정형 |
| CN111511725B (zh) * | 2017-12-19 | 2024-04-09 | 勃林格殷格翰维特梅迪卡有限公司 | 1-氰基-2-(4-环丙基-苄基)-4-(β-D-吡喃葡萄糖-1-基)-苯、L-脯氨酸和水的1:1:1共晶体的合成 |
| UY38969A (es) | 2019-11-28 | 2021-05-31 | Boehringer Ingelheim Vetmedica Gmbh | Uso de inhibidores de sglt-2 en el secado de mamíferos no humanos |
| CN118615450A (zh) | 2020-02-17 | 2024-09-10 | 勃林格殷格翰动物保健有限公司 | Sglt-2抑制剂用于预防和/或治疗猫科动物的心脏疾病的用途 |
| CA3223537A1 (en) | 2021-07-28 | 2023-02-02 | Boehringer Ingelheim Vetmedica Gmbh | Use of sglt-2 inhibitors for the prevention and/or treatment of cardiac diseases in non-human mammals excluding felines, in particular canines |
| EP4376819A1 (en) | 2021-07-28 | 2024-06-05 | Boehringer Ingelheim Vetmedica GmbH | Use of sglt-2 inhibitors for the prevention and/or treatment of hypertension in non-human mammals |
| JP2024525981A (ja) | 2021-07-28 | 2024-07-12 | ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー | ヒト以外の哺乳動物における腎疾患の予防及び／又は治療のためのｓｇｌｔ－２阻害剤の使用 |
| JP2025516857A (ja) | 2022-05-25 | 2025-05-30 | ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー | Ｓｇｌｔ－２阻害薬を含む水性医薬組成物 |
| AU2024233233A1 (en) | 2023-03-06 | 2025-09-11 | Boehringer Ingelheim Vetmedica Gmbh | Systems for delivery of liquid pharmaceutical compositions in particular comprising one or more sglt-2 inhibitor(s) |
| WO2024223388A1 (en) | 2023-04-24 | 2024-10-31 | Boehringer Ingelheim Vetmedica Gmbh | Crystalline complexes between velagliflozin and selected co-crystal forming agents, methods for their preparation and the use thereof for preparing medicaments |
| TW202508593A (zh) | 2023-05-24 | 2025-03-01 | 德商百靈佳殷格翰維美迪加股份有限公司 | 包含一或多種sglt-2抑制劑及匹莫苯坦(pimobendan)及/或替米沙坦(telmisartan)之非人類哺乳動物心臟病之組合治療及/或預防 |
| WO2024240633A1 (en) | 2023-05-24 | 2024-11-28 | Boehringer Ingelheim Vetmedica Gmbh | Combination treatment and/or prevention of renal diseases and/or hypertension in non-human mammals comprising one or more sglt-2 inhibitors and telmisartan |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2258141T3 (es) | 2001-04-11 | 2006-08-16 | Bristol-Myers Squibb Company | Complejos de aminoacidos de glucosidos c-arilo para el tratamiento de la diabetes y procedimiento. |
| US7927613B2 (en) * | 2002-02-15 | 2011-04-19 | University Of South Florida | Pharmaceutical co-crystal compositions |
| EP1581543A4 (en) * | 2003-01-03 | 2008-03-19 | Bristol Myers Squibb Co | METHODS FOR PRODUCING SGLT2 GLYCOSIS C-ARYL INHIBITORS |
| CN103435581B (zh) * | 2004-03-16 | 2015-08-19 | 贝林格尔.英格海姆国际有限公司 | 吡喃葡萄糖基取代的苯基衍生物、含该化合物的药物、其用途及其制造方法 |
| ATE491700T1 (de) * | 2005-09-08 | 2011-01-15 | Boehringer Ingelheim Int | KRISTALLINE FORMEN VON 1-CHLORO-4-(ß-D- |
| ATE517099T1 (de) * | 2006-02-15 | 2011-08-15 | Boehringer Ingelheim Int | Glucopyranosyl-substituierte benzonitril-derivate,pharmazeutische zusammensetzungen mit derartigen verbindungen, ihre verwendung und herstellungsverfahren dafür |
| TWI370818B (en) * | 2006-04-05 | 2012-08-21 | Astellas Pharma Inc | Cocrystal of c-glycoside derivative and l-proline |
| PE20080697A1 (es) * | 2006-05-03 | 2008-08-05 | Boehringer Ingelheim Int | Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion |
| US7919598B2 (en) | 2006-06-28 | 2011-04-05 | Bristol-Myers Squibb Company | Crystal structures of SGLT2 inhibitors and processes for preparing same |
| TW200817424A (en) | 2006-08-04 | 2008-04-16 | Daiichi Sankyo Co Ltd | Benzylphenyl glucopyranoside derivatives |
| PE20090185A1 (es) | 2007-03-22 | 2009-02-28 | Bristol Myers Squibb Co | Formulaciones farmaceuticas que contienen un inhibidor sglt2 |
| EP2147008A2 (en) * | 2007-05-18 | 2010-01-27 | Bristol-Myers Squibb Company | Crystal structures of sglt2 inhibitors and processes for preparing same |
| CN103319445B (zh) * | 2007-12-27 | 2016-01-20 | 阿斯利康公司 | Sglt2抑制剂的晶体结构及其制备方法 |
| CN102177147A (zh) * | 2008-08-22 | 2011-09-07 | 泰拉科斯有限公司 | 制备sglt2抑制剂的方法 |
| AU2009286380B2 (en) | 2008-08-28 | 2011-09-15 | Pfizer Inc. | Dioxa-bicyclo[3.2.1.]octane-2,3,4-triol derivatives |
| US20100167988A1 (en) | 2008-10-22 | 2010-07-01 | Auspex Pharmaceuticals, Inc. | Ethoxyphenylmethyl inhibitors of sglt2 |
| WO2011153712A1 (en) * | 2010-06-12 | 2011-12-15 | Theracos, Inc. | Crystalline form of benzylbenzene sglt2 inhibitor |
| US9145434B2 (en) | 2012-07-26 | 2015-09-29 | Boehringer Ingelheim International Gmbh | Crystalline complex of 1-cyano-2-(4-cyclopropyl-benzyl)-4-(ss-d-glucopyranos-1-yl)-benzene, methods for its preparation and the use thereof for preparing medicaments |
| PL2981269T3 (pl) | 2013-04-04 | 2024-02-05 | Boehringer Ingelheim Vetmedica Gmbh | Leczenie zaburzeń metabolicznych u zwierząt koniowatych |
-
2013
- 2013-07-23 US US13/948,751 patent/US9145434B2/en active Active
- 2013-07-25 EP EP13740309.3A patent/EP2877460B1/en active Active
- 2013-07-25 SG SG11201500574QA patent/SG11201500574QA/en unknown
- 2013-07-25 SI SI201331237T patent/SI2877460T1/sl unknown
- 2013-07-25 PL PL13740309T patent/PL2877460T3/pl unknown
- 2013-07-25 EP EP22202153.7A patent/EP4166548A1/en active Pending
- 2013-07-25 DK DK18155079.9T patent/DK3351539T3/da active
- 2013-07-25 WO PCT/EP2013/065736 patent/WO2014016381A1/en not_active Ceased
- 2013-07-25 ES ES18155079T patent/ES2937665T3/es active Active
- 2013-07-25 PT PT13740309T patent/PT2877460T/pt unknown
- 2013-07-25 AU AU2013294947A patent/AU2013294947B2/en active Active
- 2013-07-25 RS RS20230025A patent/RS63881B1/sr unknown
- 2013-07-25 TW TW102126724A patent/TW201418275A/zh unknown
- 2013-07-25 PL PL18155079.9T patent/PL3351539T3/pl unknown
- 2013-07-25 HR HRP20230081TT patent/HRP20230081T1/hr unknown
- 2013-07-25 CN CN201380037186.1A patent/CN104470908A/zh active Pending
- 2013-07-25 JP JP2015523552A patent/JP6538556B2/ja active Active
- 2013-07-25 DK DK13740309.3T patent/DK2877460T3/en active
- 2013-07-25 CA CA2878698A patent/CA2878698C/en active Active
- 2013-07-25 LT LTEP18155079.9T patent/LT3351539T/lt unknown
- 2013-07-25 SI SI201332031T patent/SI3351539T1/sl unknown
- 2013-07-25 ES ES13740309.3T patent/ES2694675T3/es active Active
- 2013-07-25 EA EA201600506A patent/EA201600506A1/ru unknown
- 2013-07-25 EA EA201500038A patent/EA025438B1/ru not_active IP Right Cessation
- 2013-07-25 MX MX2015000962A patent/MX357906B/es active IP Right Grant
- 2013-07-25 EP EP18155079.9A patent/EP3351539B1/en active Active
- 2013-07-25 PT PT181550799T patent/PT3351539T/pt unknown
- 2013-07-25 CN CN201810468431.9A patent/CN108774200A/zh active Pending
- 2013-07-25 HR HRP20181972TT patent/HRP20181972T1/hr unknown
- 2013-07-25 HU HUE18155079A patent/HUE061450T2/hu unknown
- 2013-07-25 AR ARP130102660A patent/AR091908A1/es unknown
- 2013-07-25 BR BR112015001327-9A patent/BR112015001327B1/pt active IP Right Grant
-
2018
- 2018-05-08 JP JP2018089968A patent/JP2018135384A/ja active Pending
-
2022
- 2022-07-25 FI FIEP18155079.9T patent/FI3351539T3/fi active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR091908A1 (es) | COMPLEJO CRISTALINO DE 1-CIANO-2-(4-CICLOPROPIL-BENCIL)-4-(b-D-GLUCOPIRANOS-1-IL)-BENCENO, METODOS PARA SU PREPARACION Y SU USO PARA PREPARAR MEDICAMENTOS | |
| NI201400061A (es) | Anticuerpos anti - phf - tau y sus usos | |
| CL2014002903A1 (es) | Composición geopolimérica de aluminosilicato; método de preparacion y sus usos. | |
| UY34680A (es) | Anticuerpos humanos anti-cd27, métodos, y usos | |
| BR112015002091A2 (pt) | método para a produção de um polipeptídeo, polipeptídeo, uso de um polipeptídeo e composição | |
| LT2776469T (lt) | Antikūno molekulės, pasižyminčios specifiškumu žmogaus ox40 | |
| DK3542843T3 (da) | Engangsinjektionspen til flere anvendelser | |
| CL2014002954A1 (es) | Composicion farmaceutica que contiene anticuerpos anti-il-23p19 y sus usos. | |
| BR112014012681A8 (pt) | polipeptídeo, métido para proporcionar um polipeptídeo, ácido nucleico, e, composição imunogênica | |
| DK3777840T3 (da) | Rna-formulering til immunterapi | |
| CO7121320A2 (es) | Anticuerpos anti-hla-b*27 y usos de estos | |
| PL3073959T3 (pl) | Zespól szczepiący do podawania szczepionki do młodej kury | |
| MX386584B (es) | Composiciones de liberación retardada de linaclotida. | |
| BR112012032008A2 (pt) | anticorpos s100a4 e usos terapêuticos do mesmo | |
| CO7091179A2 (es) | Nuevos derivados de tienopirimidina, procesos para su preparacion y sus usos terapeuticos | |
| MX2015012833A (es) | Composiciones antibioticas de ceftolozano. | |
| BR112015022347A2 (pt) | composição para vacinação, método para produzir uma composição para vacinação e uso de composição | |
| MX379476B (es) | Derivados de manosa, un proceso para su preparación y sus usos como un fármaco. | |
| CL2013002581A1 (es) | Compuestos derivados de indol-y -bencimidazol carboxamidas; pprocedimiento para prepararlos; uso de dichos còmpuestos para producir plaguicidas; y compuestos intermediarios. | |
| ITMI20132052A1 (it) | Impianto di alimentazione di carburante e procedimento per farlo funzionare. | |
| CR20150257A (es) | Derivados de n-(piridin-2-il)pirimidin-4-amina que contiene un grupo sulfoximina | |
| CL2013003206A1 (es) | Uso de compuestos derivados de metil y etil-carboxamidas de trifluorometil-benzotiofenos, en metodos para promover el crecimiento de plantas. | |
| BR112014026564A2 (pt) | formulação, uso de uma formulação, e, processo para a preparação de uma formulação | |
| CO7151478A2 (es) | Formulaciones estabilizadas que contienen anticuerpos anti-dll4 | |
| BR112014027808A2 (pt) | sal polimórfico do sal de oxalato de 6-o-(4-dimetilaminoetoxi) cinaroil fumagilol e métodos de produção e utilização do mesmo |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |